Pfizer drops glaucoma drug, NicOx shares slump
PARIS (Reuters) - Pfizer has decided not to take NicOx's experimental glaucoma drug PF-03187207 into final Phase III tests after a mid-stage study failed to met its primary endpoint, sending NicOx shares tumbling. 6 months ago
Reuters Click here to Read the Full Story
Digg
del.icio.us
Reddit
Stumble
Newsvine
Facebook